Edgewise Therapeutics annual depreciation and amortization
2020
2021
2022
2023
2024
2025
Edgewise Therapeutics Depreciation & Amortization Growth & History (EWTX)
Edgewise Therapeutics's depreciation and amortization was $2.3M for fiscal 2025.
View full Edgewise Therapeutics company overviewEdgewise Therapeutics annual depreciation and amortization history
| Fiscal year | Period ended | Depreciation and amortization | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $2.3M | −$24,000 | −1.05% |
| 2024 | 2024-12-31 | $2.3M | $558,000 | +32.22% |
| 2023 | 2023-12-31 | $1.7M | $1.2M | +221.93% |
| 2022 | 2022-12-31 | $538,000 | $266,000 | +97.79% |
| 2021 | 2021-12-31 | $272,000 | $87,000 | +47.03% |
| 2020 | 2020-12-31 | $185,000 | — | — |
Edgewise Therapeutics quarterly depreciation and amortization
Q1.20
Q2.20
Q3.20
Q1.21
Q2.21
Q3.21
Q1.22
Q2.22
Q3.22
Q1.23
Q2.23
Q3.23
Q1.24
Q2.24
Q3.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Depreciation and amortization | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $556,000 | $12,000 | +2.21% |
| Q1 2026 | 2026-03-31 | $590,000 | $36,000 | +6.50% |
| Q4 2025 | 2025-12-31 | $575,000 | — | — |
| Q3 2025 | 2025-09-30 | $547,000 | −$16,000 | −2.84% |
| Q2 2025 | 2025-06-30 | $544,000 | −$10,000 | −1.81% |
| Q1 2025 | 2025-03-31 | $554,000 | $29,000 | +5.52% |
| Q3 2024 | 2024-09-30 | $563,000 | $115,000 | +25.67% |
| Q2 2024 | 2024-06-30 | $554,000 | $117,000 | +26.77% |
| Q1 2024 | 2024-03-31 | $525,000 | $284,000 | +117.84% |
| Q3 2023 | 2023-09-30 | $448,000 | $283,000 | +171.52% |
| Q2 2023 | 2023-06-30 | $437,000 | $280,000 | +178.34% |
| Q1 2023 | 2023-03-31 | $241,000 | $114,000 | +89.76% |
| Q3 2022 | 2022-09-30 | $165,000 | $65,000 | +65.00% |
| Q2 2022 | 2022-06-30 | $157,000 | $106,000 | +207.84% |
| Q1 2022 | 2022-03-31 | $127,000 | $48,000 | +60.76% |
| Q3 2021 | 2021-09-30 | $100,000 | $51,000 | +104.08% |
| Q2 2021 | 2021-06-30 | $51,000 | $5,000 | +10.87% |
| Q1 2021 | 2021-03-31 | $79,000 | $39,000 | +97.50% |
| Q3 2020 | 2020-09-30 | $49,000 | — | — |
| Q2 2020 | 2020-06-30 | $46,000 | — | — |
| Q1 2020 | 2020-03-31 | $40,000 | — | — |
Edgewise Therapeutics depreciation and amortization trends
Over the last five fiscal years, Edgewise Therapeutics's depreciation and amortization increased from $185,000 to $2.3M, a change of $2.1M. The latest reported quarter, Q2 2026, shows $556,000.
About the metric
What depreciation and amortization mean
Depreciation and amortization allocate the cost of tangible and intangible assets over their useful lives. These non-cash expenses reduce reported earnings and are commonly added back when calculating EBITDA and operating cash flow.
Calculation and source
Reported depreciation and amortization
TickerStat uses a combined depreciation and amortization value when reported. If a company reports the two components separately for an aligned period, they are added together without duplicating overlapping facts. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Edgewise Therapeutics source filings ↗